Avita Medical, Inc. · NASDAQ:RCEL
Avita Medical — Investor Presentation (August 2023)
17 slides from Avita Medical's investor presentation, Aug 16, 2023
Slide 1: Accelerating Our Growth Profile
NASDAQ: RCEL ASX: AVH For personal use only Accelerating Our Growth Profile Investor Presentation August 2023
Slide 2: Forward-Looking Statements & Legal Disclaimers
Forward-Looking Statements & Legal Disclaimers Certain statements in this presentation and the accompanying oral commentary are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained
Slide 3: Who is AVITA Medical?
Who is AVITA Medical? > Regenerative medicine company transforming the standard of care for skin restoration with its For personal use only innovative cellular technology platform, the RECELL® System > RECELL System includes autologous cell harvesting device that prepares, produces, and delivers reg
Slide 4: What is RECELL?
What is RECELL? TREATMENT USING RECELL RECELL enables For personal use only 3. Autologous suspension sprayed regeneration of healthy onto treatment areas of patient skin 2. RECELL processes healthy skin and disaggregates cells to produce regenerative autologous suspension, Spray-On Skin Cells 1. Pat
Slide 5: One Platform. Multiple Indications.
One Platform. Multiple Indications. For personal use only U.S. INDICATION 2022 2023 2024 2025 Outpatient Code BURNS Ease of Use Device (Approved) RECELL GO Device Japan: Approval, Reimbursement, Launch Submission: June 30 RECELL GO Device RECELL GO Expect Launch*: Jan 2 FULL- FDA Approval*: by Dec 2
Slide 6: Highlights and Milestones
Highlights and Milestones COMMERC IAL REVENUE GROWTH For personal use only • Second quarter 2023: 42% same quarter prior year FIEL D SALES ORGANIZATIO N • Initiated recruiting and hiring process; grew from 30 to 69 towards goal of 70 • Onboarding and training underway and ahead of schedule FUL L-THI
Slide 7: Full-Thickness Skin Defects Opportunity
Full-Thickness Skin Defects Opportunity Female, pregnant 28-year-old who > suffered from a de-gloving injury For personal use only RECEIVED FDA APPROVAL ON JUNE 7, 2023 > BROADENED LABEL OF FTSD INCLUDES AFTER TRAUMATIC AVULSIO N (E.G., DEGLOVING), SURGICAL EXCISIO N (E.G., NECROTIZING SOFT TISSUE I
Slide 8: Full-Thickness Skin Defects: Market Sizing
Full-Thickness Skin Defects: Market Sizing Market Size Additional Market Opportunity Prior to FDA Approval 1 with FDA Approved Expanded Indication of FTSD1 For personal use only Traumatic Wounds Traumatic Wounds Surgical Wounds • Degloving (Open Wounds) 99,000 • Gun Shot Wounds Data • Muscle-only Fl
Slide 9: Overlap of Burns and Full-Thickness Skin Defects
Overlap of Burns and Full-Thickness Skin Defects FULL-THICKNESS SKIN DEFECTS INDICATION MEANINGFUL BROADENS BUSINESS For personal use only Sales Team Will Target a Total of 800 - 1000 Call Points ~127,000 Targeted Acute Wound 25,000 Targeted Burn Procedures + Procedures ~264,000 Expanded FTSD Proced
Slide 10: Synergies of Burns and Full-Thickness Skin Defects
Synergies of Burns and Full-Thickness Skin Defects FTSD UTILIZES IN-PATIENT REIMBURSEMENT: For personal use only Same DRG code as burns; effective immediately FTSD UTILIZES OUT-PATIENT TRANSI TIO NAL PASS-THRO UGH CODE (TPTC ): Same code as burns; effective immediately OF ~150 BURN CENTERS, 50% ARE
Slide 11: RECELL Device Evolution
RECELL Device Evolution For personal use only FIRST GENERATION DEVICE EASE OF USE DEVICE RECELL GO DEVICE • Fully manual cell disaggregation • Fewer steps and streamlined • Fully automated cell workflow, allowing for faster disaggregation and filtration set up • Simple user interface with timer • Re
Slide 12: Vitiligo Opportunity
Vitiligo Opportunity RECEIVED FDA APPROVAL ON JUNE 16, 2023 WITH STUDY Patient from a prior study at six-months > RESULTS: • Primary endpoint: proportion of study sites achieving ≥80% re- RECELL-treated area was 100% For personal use only pigmentation for RECELL-treated sites vs control at week 24 r
Slide 13: 2023: A Year of Inflection
2023: A Year of Inflection Patient from a prior study at six-months U.S. Market > FULL-THIC KNESS SKIN DEFECTS RECELL-treated area was 100% For personal use only • Received FDA approval on June 7 FTSD AND VITILIGO GREATLY EXPAND OPPORTUNITY • ~5x market expansion will fuel revenue growth re-pigmente
Slide 14: Financial Overview
Financial Overview Full-Year Strong U.S. RECELL Three-Months Ended Ended Commercial Growth For personal use only (USD in $000s) 2022 March 31 June 30 14,000 Commercial Sales 34,051 10,458 11,686 12,000 BARDA Sales 370 92 67 10,000 Total Revenue 34,421 10,550 11,753 8,000 Gross Profit 28,380 8,883 9,
Slide 15: Looking Ahead
Looking Ahead FINANCIAL GUIDANCE For personal use only COMMERCIAL REVENUE, EXCLUDING BARDA REVENUE: • Q2 2023: $13 - $14 million • 2023: $51 – $53 million GROSS PROFIT MARGIN: • 2023: 83% TO 85% FUTURE MILESTONES • Anticipate FDA approval of RECELL GO by December 27, 2023 • Expect commercial launch
Slide 16: Summary
Summary BURNS > • Core burn centers will continue to penetrate, adopt and grow • For personal use only Burns utilization will expand, accessing ~30% of market not currently called on by AVITA Medical sales team • Strong healthcare economics drive in-patient adoption; TPTC broadens coverage > FULL-TH
Slide 17: For personal use only
For personal use only